Published in J Pediatr on July 24, 2007
Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr (2008) 1.13
Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One (2010) 1.07
Management of primary sclerosing cholangitis: conventions and controversies. Can J Gastroenterol (2012) 0.86
The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther (2011) 0.84
Cystic fibrosis related liver disease--another black box in hepatology. Int J Mol Sci (2014) 0.81
CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol (2012) 0.77
What is the role of cystic fibrosis transmembrane conductance regulator dysfunction in primary sclerosing cholangitis? J Pediatr (2007) 0.75
Epithelial Anion Transport as Modulator of Chemokine Signaling. Mediators Inflamm (2016) 0.75
Cystic fibrosis from the gastroenterologist's perspective. Nat Rev Gastroenterol Hepatol (2016) 0.75
Primary Sclerosing Cholangitis: Current and Future Management Strategies. Curr Hepat Rep (2013) 0.75
Background and Epidemiology. Pediatr Clin North Am (2016) 0.75
Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 8.15
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med (2005) 5.51
Cystic fibrosis. Lancet (2009) 5.40
Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr (2006) 3.03
Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet (2011) 3.02
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet (2013) 2.91
A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain (2006) 2.91
Transcranial direct current stimulation of the unaffected hemisphere in stroke patients. Neuroreport (2005) 2.75
A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia. Arthritis Rheum (2006) 2.74
Confocal light absorption and scattering spectroscopic microscopy monitors organelles in live cells with no exogenous labels. Proc Natl Acad Sci U S A (2007) 2.56
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology (2010) 2.48
Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med (2006) 2.34
A sham-controlled trial of a 5-day course of repetitive transcranial magnetic stimulation of the unaffected hemisphere in stroke patients. Stroke (2006) 1.91
Genetic modifiers of liver disease in cystic fibrosis. JAMA (2009) 1.88
Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology (2008) 1.85
Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology (2002) 1.80
PhenCode: connecting ENCODE data with mutations and phenotype. Hum Mutat (2007) 1.75
Acute regulation of the SLC26A3 congenital chloride diarrhoea anion exchanger (DRA) expressed in Xenopus oocytes. J Physiol (2003) 1.59
Prevalence and predictors of abnormal liver enzymes in young women with anorexia nervosa. J Pediatr (2008) 1.57
Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest (2008) 1.57
Pain in chronic pancreatitis: a salutogenic mechanism or a maladaptive brain response? Pancreatology (2007) 1.52
Glucose intolerance in children with cystic fibrosis. J Pediatr (2003) 1.51
Clinical effects and brain metabolic correlates in non-invasive cortical neuromodulation for visceral pain. Eur J Pain (2010) 1.47
A systematic analysis of intronic sequences downstream of 5' splice sites reveals a widespread role for U-rich motifs and TIA1/TIAL1 proteins in alternative splicing regulation. Genome Res (2008) 1.44
Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med (2006) 1.44
Airway inflammation and infection in congenital bilateral absence of the vas deferens. Am J Respir Crit Care Med (2003) 1.44
A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes (2013) 1.43
A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy. Epilepsia (2006) 1.43
Definitions of pediatric pancreatitis and survey of present clinical practices. J Pediatr Gastroenterol Nutr (2012) 1.43
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology (2005) 1.40
Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology (2010) 1.33
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica (2008) 1.26
Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet (2012) 1.26
Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbidities. J Pediatr (2011) 1.23
Analysis of cystic fibrosis gener product (CFTR) function in patients with pancreas divisum and recurrent acute pancreatitis. Am J Gastroenterol (2004) 1.23
Direct Costs of Acute Recurrent and Chronic Pancreatitis in Children in the INSPPIRE Registry. J Pediatr Gastroenterol Nutr (2016) 1.20
Confocal light absorption and scattering spectroscopic microscopy. Appl Opt (2007) 1.18
Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest (2004) 1.18
Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene. Hum Mol Genet (2003) 1.18
Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice. J Cell Physiol (2004) 1.17
Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr (2005) 1.14
Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. Clin Diagn Lab Immunol (2004) 1.09
Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results. Hum Genet (2009) 1.08
The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet (2005) 1.08
Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr (2009) 1.01
A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis genetic modifier studies. Pediatr Pulmonol (2011) 1.00
Transcranial DC stimulation coupled with TENS for the treatment of chronic pain: a preliminary study. Clin J Pain (2009) 1.00
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology (2006) 0.99
Treatment of chronic visceral pain with brain stimulation. Ann Neurol (2005) 0.99
Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism. J Lipid Res (2008) 0.98
TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. J Immunol (2010) 0.97
Hepatitis B in children. Semin Liver Dis (2003) 0.96
Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology (2011) 0.95
Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet (2003) 0.95
Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B. Pediatrics (2009) 0.95
Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C. J Pediatr Gastroenterol Nutr (2013) 0.94
Induction of colitis in cftr-/- mice results in bile duct injury. Am J Physiol Gastrointest Liver Physiol (2004) 0.93
Transient elastography may identify Fontan patients with unfavorable hemodynamics and advanced hepatic fibrosis. Congenit Heart Dis (2014) 0.93
A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA. J Lipid Res (2008) 0.93
Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol (2006) 0.92
Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. Clin Chem (2006) 0.92
Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. J Pediatr (2012) 0.90
Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids (2007) 0.90
Evidence of increased flux to n-6 docosapentaenoic acid in phospholipids of pancreas from cftr-/- knockout mice. Metabolism (2006) 0.90
Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. J Cyst Fibros (2007) 0.89
Improving doctor-patient communication in the outpatient setting using a facilitation tool: a preliminary study. Int J Qual Health Care (2011) 0.89
Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol (2003) 0.89
Children Treated With Pegylated Interferon alfa-2a ± Ribavirin for Chronic Hepatitis C. J Pediatr Gastroenterol Nutr (2016) 0.89
Hepatitis B and C in children: current treatment and future strategies. Clin Liver Dis (2006) 0.88
Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J (2004) 0.88
Systematic review of early surgery for chronic pancreatitis: impact on pain, pancreatic function, and re-intervention. J Gastrointest Surg (2014) 0.87
Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis. Pediatr Pulmonol (2010) 0.86
Survey of breast-feeding practices and outcomes in the cystic fibrosis population. Pediatr Pulmonol (2004) 0.86
Design and implementation of INSPPIRE. J Pediatr Gastroenterol Nutr (2014) 0.85
Linoleic acid supplementation results in increased arachidonic acid and eicosanoid production in CF airway cells and in cftr-/- transgenic mice. Am J Physiol Lung Cell Mol Physiol (2010) 0.84
Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience. J Pediatr (2013) 0.84
Autoimmune pancreatitis. J Gastrointest Surg (2005) 0.84
Hepatic Inflammation May Influence Liver Stiffness Measurements By Transient Elastography in Children and Young Adults. J Pediatr Gastroenterol Nutr (2016) 0.84
Decreased peroxisome proliferator activated receptor alpha is associated with bile duct injury in cystic fibrosis transmembrane conductance regulator-/- mice. J Pediatr Gastroenterol Nutr (2006) 0.83
Management of hepatitis B in children. Clin Liver Dis (2004) 0.83
An enteral therapy containing medium-chain triglycerides and hydrolyzed peptides reduces postprandial pain associated with chronic pancreatitis. Pancreatology (2003) 0.82
Sonography-guided percutaneous liver biopsies in children. AJR Am J Roentgenol (2013) 0.82
Novel therapeutic approaches to the treatment of chronic abdominal visceral pain. ScientificWorldJournal (2006) 0.82
Ursodeoxycholic acid in cystic fibrosis-associated liver disease. J Cyst Fibros (2011) 0.81
Mesogonadal shunts for extrahepatic portal vein thrombosis and variceal hemorrhage. Liver Transpl (2005) 0.81
Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr (2010) 0.81
Evaluation of the disease liability of CFTR variants. Methods Mol Biol (2011) 0.79
Treatment of cancer pain with noninvasive brain stimulation. J Pain Symptom Manage (2007) 0.79
Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease. Chest (2012) 0.79
Approach to patients with suspected chronic pancreatitis: a comprehensive review. Pancreas (2015) 0.79
Ileal exclusion for refractory symptomatic cholestasis in Alagille syndrome. J Pediatr Surg (2007) 0.78
Lasting accelerative effects of 1 Hz and 20 Hz electrical stimulation on cortical spreading depression: relevance for clinical applications of brain stimulation. Eur J Neurosci (2005) 0.78
Laboratory tests for the diagnosis of cystic fibrosis. Am J Clin Pathol (2002) 0.78
Oral docosahexaenoic acid given to pregnant mice increases the amount of surfactant in lung and amniotic fluid in preterm fetuses. Am J Obstet Gynecol (2004) 0.78
The Frey procedure is a treatment for chronic pancreatitis, not pancreas divisum. JAMA Surg (2013) 0.78